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Introduction
TNF-receptor associated periodic syndrome (TRAPS) is
a rare, dominantly inherited periodic fever syndrome
due to mutations of the TNFRSF1A gene. The IL-1
receptor antagonist anakinra has been reported to be an
efficacious daily treatment. Canakinumab (CAN) is a
fully human monoclonal selective anti-IL-1b antibody
with a T1/2 of ~4 wks. Interim clinical and PK data of
CAN treatment in patients with active TRAPS are
presented.
Objectives
To assess the efficacy, PK, and safety of canakinumab in
patients with active TRAPS.
Methods
14 adults and 6 children (7-78 yrs) with active TRAPS
entered a 3-part trial: 4 months open-label 150 mg (or
300 mg) CAN every 4 wks followed by up to 5 months
treatment withdrawal, then 24 months open-label CAN.
Primary endpoint was complete or almost complete
response at Day 15 based on physician assessed absent
or minimal TRAPS signs/symptoms and normal or
≥70% reduced CRP and/or SAA. Those without
response by Day 8 were eligible for another 150 mg
dose and then 300 mg thereafter. Patients were observed
after last dose until relapse (5 month max) before
restarting CAN. Population PK analysis was performed
using NONMEM based on CAN concentrations deter-
mined by ELISA from blood samples collected at pre-
specified times points during the first month, at each
pre-dose of CAN, and at flares thereafter.
Results
At Day 15, 19 (95%) patients achieved complete/almost
complete response, including all 4 patients without it at
Day 8. Two patients were dose up titrated. Clinical
remission was maintained by all from Day 15 onwards
except 1 who relapsed at Day 85 (during 4 month treat-
ment period), responding to that visit’s CAN dose.
Upon CAN withdrawal, all patients relapsed after a
median of 92 days (range 72-122 days). 18 regained
response 8-27 days after restarting CAN and 2 relapsed
at final visit following last dose administered during
treatment period without follow-up at time of this analy-
sis. Population PK analysis showed that serum clearance
and volume of distribution of CAN were dependent on
bodyweight. The estimated apparent serum clearance
(CL/F) was 0.238±0.0139 L/day and the corresponding
volume of distribution (Vss/F) was 8.06 L. Following the
first dose, mean±SD observed Cmax was 16.4±4.62 μg/mL
and the median Tmax was 7.4 days. Apparent weight nor-
malized PK parameters were comparable to the PK
observed in other indications. All patients reported at
least one adverse event (AE); infections, mostly of the
upper respiratory tract, (n=15, 75%), followed by head-
ache (n=9) and abdominal pain (n=7). Two serious AEs,
an upper respiratory tract infection and a TRAPS relapse,
were reported. All patients are ongoing in the trial.
Conclusion
Canakinumab produced a rapid clinical and serological
benefit which was maintained with continued monthly
dosing. Relapse occurred at a median of 92 days after
last dose and remission achieved upon re-dosing.
Weight normalized PK parameters were comparable to
PK observed in other indications. Further studies are
needed to better define CAN therapy in TRAPS.
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